Prevalence and Risk Factors Associated With Attention-Deficit/Hyperactivity Disorder Among US Black Individuals: A Systematic Review and Meta-analysis.
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 01 2021
01 01 2021
Historique:
pubmed:
10
9
2020
medline:
18
1
2022
entrez:
9
9
2020
Statut:
ppublish
Résumé
As stated in the DSM-5, it is generally reported that the prevalence of attention-deficit/hyperactivity disorder (ADHD) is lower among Black individuals compared with the general population. However, Black individuals living in countries where they are considered a minority population group (eg, in Northern America and Europe) are underrepresented in studies evaluating ADHD. To estimate the pooled prevalence of ADHD and identify associated risk factors among US Black individuals. This systematic review and meta-analysis identified peer-reviewed studies published until October 18, 2019, using the APA PsycInfo, MEDLINE, Embase, Cochrane CENTRAL, CINAHL, ERIC, and Education Source databases. Eligible trials were published in French or English, had empirical data on the prevalence of ADHD in samples or subsamples of Black people, and were conducted in countries with Black minority populations. All studies were assessed and passed quality evaluation. The PRISMA guideline was used for extracting and reporting data. Random-effects meta-analyses were generated to estimate the prevalence of ADHD among Black individuals using the metafor package in R. Prevalence and risk factors associated with ADHD among Black individuals were identified. A total of 24 independent samples and subsamples from 21 studies published between 1979 and 2020 (154 818 Black participants) were included in this systematic review and meta-analysis. All included studies were conducted in the US. Two studies were conducted assessing adults (aged 18 years or older), 8 assessing children (0-12 years), 1 assessing adolescents (aged 13-17 years), and 13 assessing both children and adolescents. The pooled prevalence of ADHD was 14.54% (95% CI, 10.64%-19.56%). In a narrative review of the studies in this analysis, some studies found risk factors associated with ADHD, such as sociodemographic characteristics (age, sex, race, and socioeconomic status), familial factors, environmental factors, and risk behaviors, but the data did not permit a moderation analysis to assess these findings in this study. Contrary to what is stated in the DSM-5, the results of this systematic review and meta-analysis suggest that Black individuals are at higher risk for ADHD diagnoses than the general US population. These results highlight a need to increase ADHD assessment and monitoring among Black individuals from different social backgrounds. They also higlight the importance of establishing accurate diagnoses and culturally appropriate care.
Identifiants
pubmed: 32902608
pii: 2770561
doi: 10.1001/jamapsychiatry.2020.2788
pmc: PMC7489386
doi:
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-28Références
Harv Rev Psychiatry. 2005 Mar-Apr;13(2):85-101
pubmed: 16020023
Clin Psychol Rev. 2009 Feb;29(1):77-86
pubmed: 19008029
WMJ. 2013 Feb;112(1):13-7
pubmed: 23513308
Cochrane Database Syst Rev. 2017 Oct 02;10:CD009504
pubmed: 28965364
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2007 May-Jun;50(5-6):827-35
pubmed: 17514469
Lancet Psychiatry. 2018 Feb;5(2):175-186
pubmed: 29033005
Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-3-9
pubmed: 16312939
JAMA Pediatr. 2013 Mar 1;167(3):282-8
pubmed: 23338799
Stat Med. 2010 Dec 20;29(29):3046-67
pubmed: 20827667
Pediatrics. 2015 Apr;135(4):e994-1001
pubmed: 25733754
Res Dev Disabil. 2013 Nov;34(11):4203-9
pubmed: 24077069
J Youth Adolesc. 2017 Jul;46(7):1424-1451
pubmed: 27665279
J Clin Epidemiol. 2008 Jan;61(1):41-51
pubmed: 18083461
J Behav Health Serv Res. 2003 Apr-Jun;30(2):176-89
pubmed: 12710371
Cochrane Database Syst Rev. 2018 Aug 09;8:CD007813
pubmed: 30091808
J Child Adolesc Psychopharmacol. 2005 Feb;15(1):88-96
pubmed: 15741790
Neurotherapeutics. 2012 Jul;9(3):490-9
pubmed: 22976615
J Autism Dev Disord. 2014 Jan;44(1):31-40
pubmed: 23719853
Public Health Nutr. 2012 Jan;15(1):110-5
pubmed: 21729478
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1184-1193.e3
pubmed: 30395992
J Am Acad Child Adolesc Psychiatry. 2012 Jul;51(7):703-711.e2
pubmed: 22721593
Am J Psychiatry. 2007 Jun;164(6):942-8
pubmed: 17541055
J Atten Disord. 2011 Aug;15(6):516-24
pubmed: 20679156
Pediatrics. 2016 Sep;138(3):
pubmed: 27553219
J Learn Disabil. 2008 Jul-Aug;41(4):371-84
pubmed: 18560023
Children (Basel). 2019 Jan 14;6(1):
pubmed: 30646634
Can J Psychiatry. 2017 Dec;62(12):818-826
pubmed: 28616934
J Am Acad Child Adolesc Psychiatry. 2003 Jul;42(7):842-50
pubmed: 12819444
Arch Pediatr Adolesc Med. 2007 Sep;161(9):857-64
pubmed: 17768285
J Dev Behav Pediatr. 2004 Feb;25(1):41-7
pubmed: 14767355
Lancet Psychiatry. 2020 Nov;7(11):929-931
pubmed: 32652050
Cochrane Database Syst Rev. 2018 Mar 23;3:CD010840
pubmed: 29566425
Int J Methods Psychiatr Res. 2004;13(2):69-92
pubmed: 15297905
JAMA Netw Open. 2018 Aug 3;1(4):e181471
pubmed: 30646132
Psychol Sch. 2010 Apr;47(4):374-390
pubmed: 25663717
Psychiatr Serv. 2016 Feb;67(2):199-205
pubmed: 26423097
J Clin Psychiatry. 2016 Jan;77(1):52-9
pubmed: 26761486
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449
Cochrane Database Syst Rev. 2018 Jun 26;6:CD007990
pubmed: 29944175
Child Psychiatry Hum Dev. 1998 Summer;28(4):249-63
pubmed: 9628057
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120